Legal action

#AI #Drug development #Legal action

Legal issues arising from the use of artificial intelligence in drug development

Adriana Tibbitts, Alison Lehner, Frank Rahmani, and Jason Kropp from law firm Sidley Austin talk about the legal risks that AI represents in drug discovery and development.      In today’s competitive pharmaceutical industry, drug developers are seeking tools to accelerate development and maximise the commercial potential of their products in a manner that conserves resources and enables them to prioritise their… Read More

#Exclusive Content

#Drug discovery #Legal action #Life sciences #Regulatory

Proactive and forward-looking disclosure risks for pharma

Jennifer Windom, Partner at Hogan Lovells, and Bolton Smith, associate at Hogan Lovells, present the risks and considerations pharmaceutical and life sciences companies have to take when making proactive and forward-looking disclosure statements.  Publicly-traded pharmaceutical and life science companies often face a dilemma when addressing future prospects. On the one… Read More

#Exclusive Content